vs
Side-by-side financial comparison of Dole plc (DOLE) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Dole plc is the larger business by last-quarter revenue ($2.3B vs $346.4M, roughly 6.6× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 0.2%, a 27.9% gap on every dollar of revenue. On growth, Dole plc posted the faster year-over-year revenue change (10.5% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $66.5M). Over the past eight quarters, Dole plc's revenue compounded faster (3.2% CAGR vs 1.5%).
Dole plc is an Irish-American agricultural multinational corporation headquartered in Dublin, Ireland. The company is among the world's largest producers of fruit and vegetables, operating with 38,500 full-time and seasonal employees who supply some 300 products in 75 countries. Dole reported 2021 revenues of $6.5 billion.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DOLE vs HAE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $346.4M |
| Net Profit | $5.1M | $97.3M |
| Gross Margin | 6.8% | 57.2% |
| Operating Margin | 1.1% | 36.1% |
| Net Margin | 0.2% | 28.1% |
| Revenue YoY | 10.5% | 4.8% |
| Net Profit YoY | -64.6% | — |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | — | $339.0M | ||
| Q3 25 | $2.3B | $327.3M | ||
| Q2 25 | $2.4B | $321.4M | ||
| Q1 25 | $2.1B | $330.6M | ||
| Q4 24 | — | $348.5M | ||
| Q3 24 | $2.1B | $345.5M | ||
| Q2 24 | $2.1B | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | — | $44.7M | ||
| Q3 25 | $5.1M | $38.7M | ||
| Q2 25 | $10.0M | $34.0M | ||
| Q1 25 | $38.9M | $58.0M | ||
| Q4 24 | — | $37.5M | ||
| Q3 24 | $14.4M | $33.8M | ||
| Q2 24 | $80.1M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | 6.8% | 59.5% | ||
| Q2 25 | 9.0% | 59.8% | ||
| Q1 25 | 8.7% | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | 8.0% | 54.2% | ||
| Q2 24 | 9.4% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | 1.1% | 17.9% | ||
| Q2 25 | 4.3% | 16.8% | ||
| Q1 25 | 3.2% | 21.6% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | 2.3% | 15.0% | ||
| Q2 24 | 4.0% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | 13.2% | ||
| Q3 25 | 0.2% | 11.8% | ||
| Q2 25 | 0.4% | 10.6% | ||
| Q1 25 | 1.9% | 17.5% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | 0.7% | 9.8% | ||
| Q2 24 | 3.8% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | $0.05 | $0.81 | ||
| Q2 25 | $0.10 | $0.70 | ||
| Q1 25 | $0.41 | $1.17 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | $0.15 | $0.66 | ||
| Q2 24 | $0.84 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $321.0M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $1.4B | $796.3M |
| Total Assets | $4.5B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | $321.0M | $296.4M | ||
| Q2 25 | $323.1M | $292.9M | ||
| Q1 25 | $261.0M | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | $266.4M | $299.3M | ||
| Q2 24 | $225.8M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | — | $911.5M | ||
| Q3 25 | $1.4B | $849.2M | ||
| Q2 25 | $1.4B | $882.3M | ||
| Q1 25 | $1.3B | $820.8M | ||
| Q4 24 | — | $906.9M | ||
| Q3 24 | $1.4B | $878.9M | ||
| Q2 24 | $1.4B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | $4.5B | $2.4B | ||
| Q2 25 | $4.7B | $2.5B | ||
| Q1 25 | $4.5B | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | $4.5B | $2.5B | ||
| Q2 24 | $4.4B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.4M | $293.2M |
| Free Cash FlowOCF − Capex | $66.5M | $209.9M |
| FCF MarginFCF / Revenue | 2.9% | 60.6% |
| Capex IntensityCapex / Revenue | 0.9% | 9.5% |
| Cash ConversionOCF / Net Profit | 17.12× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $13.7M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | — | $93.6M | ||
| Q3 25 | $87.4M | $111.3M | ||
| Q2 25 | $18.3M | $17.4M | ||
| Q1 25 | $-78.8M | $116.6M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | $101.0M | $48.8M | ||
| Q2 24 | $40.2M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | $66.5M | $106.3M | ||
| Q2 25 | $-1.0M | $13.6M | ||
| Q1 25 | $-131.6M | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | $79.9M | $39.4M | ||
| Q2 24 | $22.8M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | 2.9% | 32.5% | ||
| Q2 25 | -0.0% | 4.2% | ||
| Q1 25 | -6.3% | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | 3.9% | 11.4% | ||
| Q2 24 | 1.1% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | 0.9% | 1.5% | ||
| Q2 25 | 0.8% | 1.2% | ||
| Q1 25 | 2.5% | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 0.8% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | 17.12× | 2.88× | ||
| Q2 25 | 1.84× | 0.51× | ||
| Q1 25 | -2.02× | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 7.01× | 1.44× | ||
| Q2 24 | 0.50× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOLE
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
